Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050323 · ClinicalTrials.gov registry record · Phase 1
Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00050323 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 30 participants.
The verdict
NCT00050323, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the safety of injections prepared from donor blood cells fused to a patient's own tumor cells which are then used to treat advanced (Stage IV) kidney cancer (renal cell carcinoma or RCC). The study will also explore the effect the injections have on the size of the tumor and the response in the patient's immune system following administration.
Interventions
- DRUG Allogeneic DCs and Autologous RCC Tumor Derived Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050323
The ClinicalTrials.gov registry entry for NCT00050323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic DCs and Autologous RCC Tumor Derived Cells is the first listed.
NCT00050323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050323 about?
NCT00050323 is a clinical study titled "Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer". The primary purpose of this study is to determine the safety of injections prepared from donor blood cells fused to a patient's own tumor cells which are then used to treat advanced (Stage IV) kidney cancer (renal cell carcinoma or RCC). The study will also explore the effect the injections have on ...
What is the current status of trial NCT00050323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-11. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00050323?
The interventions under investigation include: Allogeneic DCs and Autologous RCC Tumor Derived Cells (DRUG).
Who is sponsoring clinical trial NCT00050323?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.